Evidence map›Paper›PMID 28440324›Full record

SynthesisProstate cancer and prostatic diseases2017

Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.

R J S Calopedos, V Chalasani, R Asher, L Emmett, H H Woo

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Prostate cancer and prostatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Third-line treatment andEuropean journal of nuclear medicine and molecular imaging · 2018
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023
    Article
  8. Nuclear Medicine and Cancer Theragnostics: Basic Concepts.Diagnostics (Basel, Switzerland) · 2023
    Review
  9. Article
  10. Adoption of Lutetium-European journal of nuclear medicine and molecular imaging · 2023
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Biomedicines · 2021
    Review
  17. Article
  18. Annals of nuclear medicine · 2021
    Review
  19. European journal of nuclear medicine and molecular imaging · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

R J S CalopedosDepartment of Uro-Oncology, Chris O'Brien Lifehouse, University of Sydney, Sydney, NSW, Australia.
V ChalasaniNorthern Clinical School, University of Sydney, Sydney, NSW, Australia.
R AsherDepartment of Uro-Oncology, Chris O'Brien Lifehouse, University of Sydney, Sydney, NSW, Australia.
L EmmettNuclear Medicine Department, St Vincent's Hospital, Sydney, NSW, Australia.
H H WooDepartment of Uro-Oncology, Chris O'Brien Lifehouse, University of Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPromising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 (

methodsA systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and assessed methodological quality. The main outcome of interest was antitumour biochemical response of

resultsA total of 10 studies were included in the analysis giving a total sample size of 369, 220 (of 334 analysable) experienced any PSA decline. The pooled proportion of patients with any PSA decline was 68% (95% confidence interval (CI): 61-74). The I

conclusionsThis review suggests promising early results for the treatment of mCRPC, especially from patients treated with the more recently developed radioligands. Overall, our meta-analysis showed that approximately two-thirds of patients had a biochemical response. Randomised-controlled trials would be necessary to verify its effectiveness against current systemic therapies and create an ideal treatment protocol.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIHumansKallikreinsLigandsLutetiumMaleProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsTreatment OutcomeAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIKallikreinsKLK3 protein, humanLigandsLutetiumLutetium-177Prostate-Specific AntigenRadioisotopesRadiopharmaceuticals

Identifiers

PMID28440324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.